Uncontrolled schizophrenia symptoms are troublesome and debilitating for patients, and most often a result of non-adherence to their treatment plan. Non-adherence has been shown to be a predictor of poor outcomes in schizophrenia patients, with significantly higher utilization of healthcare resources and hospitalizations.1 This program focuses on members of the interdisciplinary psychiatric healthcare team about long-acting injectable antipsychotics (LAIs) as a viable option to address non-adherence in schizophrenia patients, subsequently improving health outcomes for these patients.
The goal of this online project is to educate/train interdisciplinary psychiatric healthcare team members on the uses of Long-acting Injectable antipsychotics (LAIs) to successfully manage their schizophrenia patients The program is divided into TWO parts. Part ONE includes self-paced, online video-based activities that consists of a series of 30-minute modules. Part TWO includes a live, interactive webinar designed to be a fully interactive discussion among participants and experts. The discussion will address the content in part ONE, answer any questions, and examine how the participants have incorporated their knowledge of this content into their current practice.
Overall Learning Objectives
- Discuss the impact of long-acting injectable antipsychotic agents on adherence and outcomes in schizophrenia patients.
- Identify ideal patients that are candidates for long-acting injectable antipsychotic therapy.
- Compare and contrast currently available long-acting injectable antipsychotic agents with regards to indication, adverse effect profile, initiation regimen and dosing.
- Select an appropriate long-acting injectable antipsychotic for a patient, based on individual patient characteristics and practice settings.
- Explain the potential opportunity for pharmacists to affect patients’ adherence to their long-acting injectable antipsychotic regimens.
Live Webinar May 9 12:00 to 1:00 CT:
A live webinar with the instructor, Dr. Saklad, will take place on May 9 at 12 noon CT. This webinar is optional, but we invite all who completed the online modules to attend. Participants will be able to submit questions prior to and during the webinar, so direct practice questions can be answered.
After registering and completing the online video modules, click on the tab below titled: Live Webinar for instructions on how to dial in to the dicussion.
Financial Support: This program has been funded through an educational grant from Alkermes.
Disclosure: Dr. Saklad, presenting faculty, has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:
- Employee of Texas Department of Health Services San Antonio & The University of Texas at Austin College of Pharmacy
- Speakers Bureau: Alkermes, Neurocrine
- Consultant: Alkermes, NCS Pearson, Otsuka / Lundenbeck
- Other: Member of Pharmacists Foundation, Business Development Council for San Antonio
Review of Conflicts and Relationship Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this program, UT College of Pharmacy faculty who are not affiliated with the program review the content and report any potential conflict of interest to the CPE Director. From the review, no conflicts were documented. In addition to the reviews, evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest. If conflict issues were discovered, they are addressed with speakers to and appropriate changes would be made and documented in this space.
This program is intended for pharmacists (inpatient psych beds; community mental health and/or an interest in administering LAIs), physicians/psychiatrists, and advanced nurse practitioners (psychiatric-focused), who are seeking an evidence-based approaches to the use of long-acting injectable (LAI) antipsychotics for the management of schizophrenia.
AACME Continuing Medical Education Statement:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The UT Health San Antonio Joe R. & Teresa Lozano Long School of Medicine and The University of Texas at Austin College of Pharmacy. The Joe R. & Teresa Lozano Long San Antonio School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Long School of Medicine designates this live activity for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Physician Assistants (AAPA), American Academy of Nurse Practitioners (AANP) and the American Nurses Credentialing Center (ANCC) accepts certificates of attendance for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Healthcare professionals receiving a certificate of attendance should consult with their licensing board for information on applicability and acceptance.
ACPE Continuing Phamracy Education Statement
The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This online activity is approved for a total 0.3 CEUs (3.00 contact hours) of continuing education credit. In order to receive all 3.00 contact hours of CE credit, complete the online post-tests, complete each module evaluation, and complete the live webinar evaluation.